Clinical Trials Logo
  1. Home
  2. Glaucoma
  3. NCT00573638
  4. Details
NCT00573638 Clinical Trial

Effects of Xal-Ease on Patient Compliance With Xalatan

Glaucoma Clinical Trial

— Xal-Ease  

Official title:
The Effects of the Xal-Ease Delivery Aid Device on Patient Compliance With Xalatan Eye Drops

Clinical Trial Details — Status: Unknown status

Administrative data
NCT number NCT00573638
Other study ID # 05-02-266
Secondary ID Guarantor or CPI
Status Unknown status
Phase N/A
First received December 7, 2007
Last updated August 7, 2008
Start date February 2005
Est. completion date December 2009

Study information
Verified date August 2008
Source Augusta University
Contact Christian D. Nilson, MD
Phone 706-721-1150
Email cnilson@mail.mcg.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study hypothesis is that the Xal-Ease with increase patient compliance with XALATAN

Recruitment information / eligibility
Status Unknown status
Enrollment 50
Est. completion date December 2009
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria:

- 40 to 80 years old

- Diagnosis warranting treatment with Xalatan eye drops.

- ambulatory and well functioning

Exclusion Criteria:

- non-ambulatory

- less than 40 or greater than 80 years old

- Not using Xalatan eye drops

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• Xal-Ease device to be used with Xalatan eye drops
This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.

Locations
Country Name City State
United States Medical College of Georgia Health Inc Augusta Georgia

Sponsors (2)
Lead Sponsor Collaborator
Augusta University Pfizer

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary The primary outcome measure is compliance with the medication XALATAN using and not using the Xal-Ease delivery aid for their glaucoma treatment. six months
Secondary To determine if any of the other factors mentioned in the survey affect compliance to their medical regimen six months
Secondary To see whether or not the Xal-Ease device helps patients conserve medication. ie - aids in drops not distilled in the eye. 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A